VEGFA and diabetic retinopathy: Accordingly, these results imply that the durability of anti-VEGF treatments differs between diabetic retinopathy and DME; therefore, diabetic retinopathy progression should be monitored carefully when the treatment intervals are extended with TER based on DME state.